JP2016513734A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513734A5 JP2016513734A5 JP2016502780A JP2016502780A JP2016513734A5 JP 2016513734 A5 JP2016513734 A5 JP 2016513734A5 JP 2016502780 A JP2016502780 A JP 2016502780A JP 2016502780 A JP2016502780 A JP 2016502780A JP 2016513734 A5 JP2016513734 A5 JP 2016513734A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- drug
- disease
- serotonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 5
- 229960003987 melatonin Drugs 0.000 claims 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims 4
- MEVXSUZBFYZPHZ-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CC(=O)N=C1N MEVXSUZBFYZPHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960003105 metformin Drugs 0.000 claims 3
- 229940076279 serotonin Drugs 0.000 claims 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 claims 2
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 claims 2
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 claims 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229960004329 metformin hydrochloride Drugs 0.000 claims 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical group Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- -1 thienopyridone Chemical compound 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- KCWQSNFJXVMEQC-UHFFFAOYSA-N 2-(5-hydroxy-1h-indol-2-yl)acetic acid Chemical class OC1=CC=C2NC(CC(=O)O)=CC2=C1 KCWQSNFJXVMEQC-UHFFFAOYSA-N 0.000 claims 1
- BYNFKPVCVMZGOI-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-indol-5-ol;sulfuric acid Chemical compound OS([O-])(=O)=O.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 BYNFKPVCVMZGOI-UHFFFAOYSA-N 0.000 claims 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 claims 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 229960004111 buformin Drugs 0.000 claims 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229960003243 phenformin Drugs 0.000 claims 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229940026197 serotonin hydrochloride Drugs 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793407P | 2013-03-15 | 2013-03-15 | |
| US61/793,407 | 2013-03-15 | ||
| PCT/US2014/028413 WO2014144130A2 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513734A JP2016513734A (ja) | 2016-05-16 |
| JP2016513734A5 true JP2016513734A5 (enExample) | 2017-03-30 |
Family
ID=51538303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502780A Pending JP2016513734A (ja) | 2013-03-15 | 2014-03-14 | Ａｍｐｋ活性化剤及びセロトニン作動薬を含む医薬組成物並びにそれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140350064A1 (enExample) |
| EP (1) | EP2983473A4 (enExample) |
| JP (1) | JP2016513734A (enExample) |
| KR (1) | KR20160005341A (enExample) |
| CN (1) | CN105636438A (enExample) |
| AR (1) | AR095631A1 (enExample) |
| AU (1) | AU2014227807B2 (enExample) |
| BR (1) | BR112015023922A2 (enExample) |
| CA (1) | CA2909633A1 (enExample) |
| CL (1) | CL2015002680A1 (enExample) |
| HK (1) | HK1222297A1 (enExample) |
| IL (1) | IL241587B (enExample) |
| MX (1) | MX2015012760A (enExample) |
| RU (1) | RU2015143438A (enExample) |
| TW (1) | TW201444552A (enExample) |
| WO (1) | WO2014144130A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180071269A1 (en) * | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| ES2567105B1 (es) * | 2014-09-19 | 2017-02-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| US10463649B2 (en) | 2015-06-08 | 2019-11-05 | Texas Tech University System | Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors |
| KR101663543B1 (ko) * | 2015-07-29 | 2016-10-07 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| WO2017018752A1 (ko) * | 2015-07-29 | 2017-02-02 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| WO2017023833A1 (en) * | 2015-08-01 | 2017-02-09 | Petti Stephen J | Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature |
| CN105541665A (zh) * | 2016-02-18 | 2016-05-04 | 江苏大学 | 一种抗肿瘤药物化合物及制备方法和应用 |
| KR101838622B1 (ko) * | 2016-09-20 | 2018-03-14 | 김브라이언 | 아디포넥틴 수용체에 대한 작용제 펩타이드 |
| KR20190096949A (ko) | 2016-10-05 | 2019-08-20 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 소분자 ampk 활성화제 |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| KR102506333B1 (ko) | 2016-12-20 | 2023-03-06 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피흡수 치료 시스템 |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| CN107252425A (zh) * | 2017-07-12 | 2017-10-17 | 上海华堇生物技术有限责任公司 | 去氢延胡索素的药物用途 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
| US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
| CN108159044A (zh) * | 2018-02-26 | 2018-06-15 | 华中科技大学 | 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN111960985A (zh) * | 2018-08-08 | 2020-11-20 | 中国人民解放军总医院 | 抗肿瘤化合物 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN109771424B (zh) * | 2019-03-11 | 2021-03-16 | 马慧 | 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用 |
| CN109793727A (zh) * | 2019-03-13 | 2019-05-24 | 湖北科技学院 | 一种有效抗恶性肿瘤的药物组合物及其应用 |
| US12428378B2 (en) | 2019-09-10 | 2025-09-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing level of phosphorylated AMPK protein |
| CN110559298A (zh) * | 2019-10-28 | 2019-12-13 | 中国药科大学 | 一种天然化合物Egenine用于制备抗肾纤维化药物的用途 |
| AU2020372682A1 (en) * | 2019-10-31 | 2022-06-09 | Jd Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| EP4186893A4 (en) * | 2020-07-22 | 2025-02-05 | Geneora Pharma (Shijiazhuang) Co., Ltd. | 5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof |
| AU2022234302A1 (en) | 2021-03-10 | 2023-10-12 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| KR20240046175A (ko) | 2021-07-07 | 2024-04-08 | 테란 바이오사이언시스 인코포레이티드 | N,n-디메틸트립타민 및 관련 사이키델릭스 및 이의 용도 |
| CA3237988A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| TW202440068A (zh) * | 2022-12-05 | 2024-10-16 | 美商恩維達醫療公司以恩維達生物科學公司之名營業 | 用於治療搔癢之諾卡酮（ｎｏｏｔｋａｔｏｎｅ） |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| EP1762234A4 (en) * | 2004-06-28 | 2010-05-05 | Kao Corp | AMPK AKTIVATOR |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
| US20120183600A1 (en) * | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| BRPI0806774A2 (pt) * | 2007-01-16 | 2011-09-13 | Ipintl Llc | composição para tratamento de sìndrome metabólica |
| WO2011112167A1 (en) * | 2009-03-13 | 2011-09-15 | Reset Therapeutics, Inc. | Compositions and methods for diabetes treatment |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
-
2014
- 2014-03-14 MX MX2015012760A patent/MX2015012760A/es unknown
- 2014-03-14 CA CA2909633A patent/CA2909633A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/028413 patent/WO2014144130A2/en not_active Ceased
- 2014-03-14 JP JP2016502780A patent/JP2016513734A/ja active Pending
- 2014-03-14 BR BR112015023922A patent/BR112015023922A2/pt not_active IP Right Cessation
- 2014-03-14 CN CN201480028057.0A patent/CN105636438A/zh active Pending
- 2014-03-14 US US14/212,734 patent/US20140350064A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029838A patent/KR20160005341A/ko not_active Withdrawn
- 2014-03-14 HK HK16109576.5A patent/HK1222297A1/zh unknown
- 2014-03-14 EP EP14763798.7A patent/EP2983473A4/en not_active Withdrawn
- 2014-03-14 TW TW103109748A patent/TW201444552A/zh unknown
- 2014-03-14 AU AU2014227807A patent/AU2014227807B2/en not_active Ceased
- 2014-03-14 RU RU2015143438A patent/RU2015143438A/ru unknown
- 2014-03-17 AR ARP140101258A patent/AR095631A1/es unknown
-
2015
- 2015-09-14 CL CL2015002680A patent/CL2015002680A1/es unknown
- 2015-09-16 IL IL241587A patent/IL241587B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513734A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2016537347A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013199505A5 (enExample) | ||
| JP2016056183A5 (enExample) | ||
| JP2012184234A5 (enExample) | ||
| JP2012520883A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2015515475A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2010535252A5 (enExample) | ||
| JP2015145426A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| JP2013505282A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2018529742A5 (enExample) | ||
| JP2012523430A5 (enExample) | ||
| JP2013542246A5 (enExample) | ||
| JP2010518061A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2016510326A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |